Press Release

Geneos Therapeutics Presents Personalized Neoantigen-Based DNA Therapy That Sustains Anti-tumor Immunity in Brain Cancer Patients and Offers a Path to Dynamic Therapy

PHILADELPHIA, PA, November 16, 2026 / Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-targeted personalized DNA immunotherapy for cancer (PIC), presented follow-up data from extended treatment of two patients with high grade glioma which demonstrates the feasibility of sustained immune surveillance and dynamic therapy in clinical practice. These data were … Read more

Geneos Therapeutics Announces Scientific Meeting Presentation of Sustained Immunosurveillance and Progression-free Survival in Two Brain Cancer Patients Treated with Neoantigen Targeted Personalized DNA Immunotherapy

–Presentation to be given at the 2026 Society for Neuro-Oncology Annual Meeting will highlight two high grade glioma patients with sustained immunosurveillance in brain cancer offering a promising treatment path —   Philadelphia, PA – November 2, 2026 – Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen targeted personalized DNA … Read more

Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer

Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer The study evaluates patients with liver cancer at high risk of recurrence following surgical resection Julie Rosenberg, MD, appointed to leadership team as Chief Medical Officer PHILADELPHIA, PA / OCTOBER 21, 2026 / Geneos Therapeutics, a clinical stage biotherapeutics … Read more

Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Philadelphia, PA – March 6, 2024 – Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced the upcoming presentation of two posters sharing new clinical data from its Phase 1b/2a GT-30 study of GNOS-PV02, a personalized neoantigen DNA vaccine, in patients with advanced hepatocellular carcinoma, … Read more